NCT04418141CompletedPhase 1
A Phase I, Open Label, Multi-Center, Dose Escalation Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CN1 in Patients With Advanced Solid Tumors or B-cell Lymphoma
Curon Biopharmaceutical (Australia) Co Pty Ltd1 site in 1 country13 target enrollmentStarted: July 2, 2020Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Enrollment
- 13
- Locations
- 1
- Primary Endpoint
- To determine dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and/or recommended Phase II dose (RP2D) of CN1 administered to patients with advanced solid tumor or B-cell lymphoma.
Study Overview
Brief Summary
This study is the first-in-human clinical trial of CN1 to evaluate the safety, tolerability, pharmacokinetic (PK) profile and preliminary efficacy of CN1 in patients with advanced solid tumors or B-cell lymphoma. This study will provide a basis for further clinical development of CN1.
Detailed Description
CN1 could promote T cell activation and cytokine secretion, thereby enhancing the function of CD4+ and CD8+ T cells, and could also regulate Treg cells, thus CN1 is considered to enhance the anti-tumor immune response and have potential antitumor activity.
In this multicenter, open-label, dose-escalation Phase I study six dose levels are planned. Participants will receive CN1 by IV infusion on Day 1 of each cycle (every 3 weeks). After completion of treatment cycles, the participant will be assessed by the Principal Investigator and/or Safety Monitoring Committee (SMC).
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age ≥ 18 years and ≤ 75 years old, male or female;
- •Subjects with histologically or cytologically diagnosed advanced malignant solid tumors or B-cell lymphoma who have failed on, or are intolerant to, standard therapy, for whom there are no standard of care regimens, or who are otherwise not eligible for standard therapy at this stage;
- •Subjects with Eastern Cooperative Oncology Group (ECOG) performance score of 0-1;
- •Females must be non-pregnant and non-lactating, and must use an acceptable, highly effective double contraception from screening until the end of the follow-up period.
- •Subjects must be able to understand and sign the paper informed consent before any study specific procedure.
Exclusion Criteria
- •Received anti-tumor treatment such as radiotherapy, chemotherapy, biotherapy, endocrine therapy, immunotherapy, etc., within 4 weeks prior to the first dose of study drug.
- •Received other investigational agents (not yet approved by any regulatory agency) within 4 weeks prior to the first dose of study drug;
- •Major organ surgery (excluding puncture biopsy) or significant trauma within 4 weeks prior to the first dose of study drug;
- •Systemic application of corticosteroids (prednisone > 10 mg/day or equivalent) or other immunosuppressive agents within 14 days prior to the first dose of study drug;
- •Exceptions: topical, ocular, intra-articular, intranasal, and inhaled corticosteroids, or short-term corticosteroids for prophylaxis (e.g., contrast allergy prophylaxis).
- •Use of live attenuated vaccine within 4 weeks prior to the first dose of study drug;
- •Clinically symptomatic metastases to the central nervous system or meninges, or other evidence of uncontrolled metastases to the central nervous system or meninges of the subject;
- •Active infection and in current need of, or likely to need, intravenous anti-infective therapy;
- •History of immunodeficiency, including history of any positive test result for human immunodeficiency virus (HIV) antibody;
- •Active hepatitis B or hepatitis C virus infection.
- •Subjects with active or previous autoimmune diseases (e.g. systemic lupus erythematosus, rheumatoid arthritis, vasculitis, etc.), except subjects with clinically stable autoimmune thyroid disease;
- •Subjects with mental disorders or other conditions that pose high non-compliance risks in the opinion of the investigator;
Arms & Interventions
Single Arm
Experimental
Five planned CN1 dose levels of 0.03 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, and 10 mg/kg.
Subjects will receive CN1 by intravenous infusion (IV) on Day 1 (D1) of each cycle (once every 3 weeks per cycle).
Intervention: CN1 (Drug)
Outcomes
Primary Outcomes
To determine dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and/or recommended Phase II dose (RP2D) of CN1 administered to patients with advanced solid tumor or B-cell lymphoma.
Time Frame: 21 Days after the first dose i.e. starting dose level 0.03 mg/kg
DLT is measured in the observation period of 21 days after the first dose i.e. starting dose level 0.03 mg/kg. if the enrolled subject does not experience a study drug related Grade 2 or higher adverse event (AE) per NCI-Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, the subject will start to receive the next designated dose level of 0.3 mg/kg in the second 21 days dosing cycle.
Secondary Outcomes
- To assess the pharmacokinetic (PK) profile of CN1 in patients with advanced solid tumor or B-cell lymphoma through Area under the plasma concentration-time curve(Measurement is through treatment completion starting from Week 1 up to End of Treatment, assessed up to an average of 10 weeks.)
- To assess the pharmacokinetic (PK) profile of CN1 in patients with advanced solid tumor or B-cell lymphoma through Tmax(Measurement is through treatment completion starting from Week 1 up to End of Treatment, assessed up to an average of 10 weeks.)
- To assess the safety and tolerability of CN1 in patients with advanced solid tumor or B-cell lymphoma through Physical Exam(From baseline(Week 1) to 90 days after the last dose)
- To assess the safety and tolerability of CN1 in patients with advanced solid tumor or B-cell lymphoma through Adverse Events/Serious Adverse Events(From baseline(Week 1) to 90 days after the last dose)
- To assess the pharmacokinetic (PK) profile of CN1 in patients with advanced solid tumor or B-cell lymphoma through Apparent volume of distribution at steady state(Measurement is through treatment completion starting from Week 1 up to End of Treatment, assessed up to an average of 10 weeks.)
- To assess the pharmacokinetic (PK) profile of CN1 in patients with advanced solid tumor or B-cell lymphoma through Accumulation factor based on AUC 0-τ(Measurement is through treatment completion starting from Week 1 up to End of Treatment, assessed up to an average of 10 weeks.)
- To assess the immunogenicity to CN1 in patients with advanced solid tumor or B-cell lymphoma through ADA testing(Measurement is through treatment completion starting from Week 1 up to End of Treatment, assessed up to an average of 10 weeks.)
- To explore the anti-tumor efficacy of CN1 in patients with advanced solid tumor or B-cell lymphoma through ORR analysis(Measurement is from Week 1, until the 90 days after the last dose, date of first documented progression or unacceptable toxicity, withdrawal of consent, subject being lost to follow-up, or death, whichever occurs first.)
- To explore the anti-tumor efficacy of CN1 in patients with advanced solid tumor or B-cell lymphoma through DCR analysis.(Measurement is from Week 1, until the 90 days after the last dose, date of first documented progression or unacceptable toxicity, withdrawal of consent, subject being lost to follow-up, or death, whichever occurs first.)
- To explore the anti-tumor efficacy of CN1 in patients with advanced solid tumor or B-cell lymphoma through DoR analysis.(Measurement is from Week 1, until the 90 days after the last dose, date of first documented progression or unacceptable toxicity, withdrawal of consent, subject being lost to follow-up, or death, whichever occurs first.)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Active, not recruiting
Phase 1
A First-in-Human, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BJ-005 in Patients With Advanced Solid Tumor or LymphomaAdvanced Solid Tumor or LymphomaNCT05115292BJ Bioscience, Inc.85
Recruiting
Phase 1
Study in Patients With Advanced Solid Malignancies to Evaluate the Safety of FTL001Solid TumorNCT06410092Sound Biopharmaceuticals Ltd.44
Active, not recruiting
Phase 1
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid TumorsGastric CancerUrothelial CarcinomaCervical CancerColorectal CancerHCCMelanomaTNBCEsophageal CancerNSCLCLocally Advanced or Metastatic Solid TumorsHNSCCClear Cell RCCNCT05581004Genentech, Inc.165
Completed
Phase 1
Clinical Trial to Evaluate the Safety of RQ-01 in SARS-CoV-2 Positive SubjectsSARS CoV 2 InfectionInfectious DiseaseSymptomatic COVID-19 Infection Laboratory-ConfirmedCOVID-19NCT06063330Red Queen Therapeutics, Inc.66
Completed
Phase 1
A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK117 as Monotherapy or in Combination With AK104Neoplasms MalignantNCT04349969Akesobio Australia Pty Ltd38